IE57352B1 - Composition having improved pharmaceutical activity and use of it for veterinary purposes - Google Patents
Composition having improved pharmaceutical activity and use of it for veterinary purposesInfo
- Publication number
- IE57352B1 IE57352B1 IE1088/84A IE108884A IE57352B1 IE 57352 B1 IE57352 B1 IE 57352B1 IE 1088/84 A IE1088/84 A IE 1088/84A IE 108884 A IE108884 A IE 108884A IE 57352 B1 IE57352 B1 IE 57352B1
- Authority
- IE
- Ireland
- Prior art keywords
- antibiotic
- composition
- benzylpenicillin
- compound
- oxytetracycline
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 230000000694 effects Effects 0.000 title description 4
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 24
- 230000003115 biocidal effect Effects 0.000 claims abstract description 17
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims abstract description 13
- 230000002195 synergetic effect Effects 0.000 claims abstract description 9
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims abstract description 6
- 235000019371 penicillin G benzathine Nutrition 0.000 claims abstract description 6
- 229940056360 penicillin g Drugs 0.000 claims abstract description 6
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 claims abstract description 4
- 230000001338 necrotic effect Effects 0.000 claims abstract description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 239000004100 Oxytetracycline Substances 0.000 claims description 5
- 229960000625 oxytetracycline Drugs 0.000 claims description 5
- 235000019366 oxytetracycline Nutrition 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 230000002458 infectious effect Effects 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 3
- 208000031888 Mycoses Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 210000004400 mucous membrane Anatomy 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- UBDNTYUBJLXUNN-IFLJXUKPSA-N Oxytetracycline hydrochloride Chemical compound Cl.C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O UBDNTYUBJLXUNN-IFLJXUKPSA-N 0.000 claims description 2
- WHRVRSCEWKLAHX-LQDWTQKMSA-N benzylpenicillin procaine Chemical compound [H+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 WHRVRSCEWKLAHX-LQDWTQKMSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 206010025482 malaise Diseases 0.000 claims description 2
- 206010034674 peritonitis Diseases 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229940095783 procaine benzylpenicillin Drugs 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 229960004063 propylene glycol Drugs 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- ZIBLWMZMPUUCNK-UHFFFAOYSA-L S([O-])(O)=O.C=O.[Mg+2].S([O-])(O)=O Chemical compound S([O-])(O)=O.C=O.[Mg+2].S([O-])(O)=O ZIBLWMZMPUUCNK-UHFFFAOYSA-L 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- 239000000395 magnesium oxide Substances 0.000 claims 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 3
- 210000004877 mucosa Anatomy 0.000 abstract description 3
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 abstract 1
- 229960004919 procaine Drugs 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 4
- 206010017564 Fusobacterium infections Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028846 Necrobacillosis Diseases 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 241001655326 Corynebacteriales Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033971 Paratyphoid fever Diseases 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000607683 Salmonella enterica subsp. enterica serovar Pullorum Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046793 Uterine inflammation Diseases 0.000 description 1
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 1
- GGJMJEJCHREISP-UHFFFAOYSA-M [O-2].[Mg+2].S([O-])(O)=O.C=O.[Mg+2] Chemical compound [O-2].[Mg+2].S([O-])(O)=O.C=O.[Mg+2] GGJMJEJCHREISP-UHFFFAOYSA-M 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 208000003796 chancre Diseases 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 229940063650 terramycin Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
An antibiotic composition comprising simultaneously oxytetracyclin, procain benzylpenicillin and colistin sulphate has a combined synergic activity susceptible to cure necrotic diseases and mucosa troubles for which no efficient remedy has been found heretofore.
Description
Composition having improved pharmaceutical activity and use of it for veterinary purposes The present invention concerns an antibiotic composition comprising, in injectible form, a synergistic mixture of an antibiotic of the oxytetracycline type and an antibiotic of the benzylpenicillin type intended to combat certain disorders caused by bacteria.
The use of antibiotics has spread widely and a large number of different antibiotics having a specific particular effect or a wide spectrum of action are currently available on the market.
These antibiotics are widely used at present for the treatment of mammals, particularly in veterinary medicine.
For various reasons, it is recognised that a large number of products t cannot combat certain complaints, in particular some infectious > diseases, or furthermore that they lose their effectiveness, probably as a result of modifications in the microbial, viral or cryptogramic strains.
It is known from Belgian Patent No. 505709 (Pfizer) that some antibiotic compositions containing simultaneously an antibiotic of the -2oxytetracycline or terramycin type and an antibiotic of the penicillin type are surprisingly effective against many different types of bacteria, particularly against various infectious microorganisms of the Salmonella and Pseudomonas groups, even though when used individually they have only a weak therapeutic value against the said microorganisms. Among the maladies caused by the Salmonel las one can mention for Man : Paratyphoid fever, Salmonel lie Enterocolitis, Pneumonia, and Osteomyelitis. Certain bacteria of the Salmonella group are also the cause of dangerous diseases in animals, such as the infection due to Salmonella pullorum in poultry.
The present invention is also based upon obtaining a surprising synergy between the two above-mentioned antibiotics.
It is based on the discovery that the addition of colistin sulphate or Multimycine to a mixture of the two above-mentioned antibiotics increases in a remarkable manner the spectra of applicability of the composition and provides a composition capable of curing ailments for which there is no good remedy today.
It concerns an antibiotic composition comprising, in injectable form, a synergistic mixture of an antibiotic of the oxytetracycline type and an antibiotic of the benzylpenicillin type intended to combat certain illnesses caused by bacteria, essentially characterised in that it comprises, in addition to the said two antibiotics, also an antibiotic of the Multimycine type in a weight ratio oxytetracycline: benzylpenicillin: Multimycine in a range varying from 10 to 30, preferably 20 of the first compound, 200 to 300, preferably 150, of the second compound and 1 to 15, preferably 7, of the third compound.
The synergistic composition of the invention finds its preferred veterinary application, taking account of its effectiveness, for combatting all the infections of the mucosa or mucous membranes, in particular the mycoses caused by fungi and all the necrotic illnesses, for example necrosis, lingual necrobacillosis and chancre or canker. -3Another field of application is constituted by the treatment of Peritonitis, Metritis, infectious Pneumonia in foals, (Coryne bacterial influenza) and the white sickness in Bovines (ulcers on the hooves) or whitlow.
These fields of application are not however limiting because other ailments of the same kind can be treated effectively with the aid of the composition of the invention.
The invention will be described further in detail with the help of an Example intended to illustrate its new and inventive character, but without either the precise composition or the Galenic form being considered as a limitation.
A Galenic form of the antibiotic composition according to the invention was prepared by mixing the following constituents for 100 ml: 1/ Oxytetracycl ine HCl 2/ Procaine Benzylpenicillin 3/ Colistin Sulphate 4/ Polyvidone Aqua distillata / Magnesium formaldehyde bisulfite Magnesium oxide Methyl parahydroxybenzoate Sodium citrate Sodium carboxymethyl cellulose Propyl para hydroxybenzoate Polyvinyl pyrrolidone 6/ Propyleneglycol 926 pg 24000 pg to 100 pg constituent of the solvent ad 1 ml 7 mg mg 0.68 mg 3.5 mg diluent 0.12 mg diluent mg as far as solvent The mixture is made first by mixing the compounds 1/ and 2/ together, then adding the compound 3/ to them, after which all the compounds set out under 4/ and 5/ are added. -4The preparation in liquid form in the proportions indicated above is injected in a ratio of 20 ml per 100 kg of body weight to calves; the dosage can go to 50 ml per head of adult live-stock.
This dosage represents for 20 ml, 6.25 million International Units of anti bi otics.
The composition as described has proved particularly effective for λ combatting the infections of the Mucosa or mucous membranes, in particular the mycoses caused by fungi which, in numerous cases, in the absence of treatment with the aid of the synergistic composition of the invention, would necessitate the slaughter of the beast or surgical interventions. A young animal seriously attacked by lingual necrobacillosis and which refused to drink, was able to be cured within 24 hours.
The composition has proved to be also very effective for the treatment of the other ailments mentioned above, even though the use of the cited antibiotics individually shows practically no effect.
It is appropriate to note that as a variant it is possible to add other antibiotics to the synergistic mixture as described, even though these antibiotics, for the most part known compounds, do not seem to augment the effectiveness of the synergistic composition of the invention.
It should be clearly understood that numerous modifications can be made to the embodiment of the invention which has been described and that the skilled man in particular can make numerous variations in the choice, particularly of the excipients, supports or diluants. In principal, therefore, the invention covers all the synergistic compositions of the invention with the supports, diluants and \ excipients habitually used in Pharmacology.
It is fitting to note that the above-mentioned range of application is given by way of example and is not in any way limitative. Likewise, the particular posology (dosage) in each compound preparation can be -5varied and the preparations of the invention find their application just as much for prevention as for cure, in surgical interventions, etc.
The invention extends to all these variants of application, composition, or of preparation.
Claims (5)
1. Antibiotic composition comprising, in an injectible form, a synergistic mixture of an antibiotic of the Oxytetracycline type and an antibiotic of the Benzylpenicillin type intended to combat certain disorders due to bacteria, characterised in that it comprises, in addition to the two said antibiotics, also an antibiotic of the Multimycine type.
2. Composition according to claim 1, characterised in that the antibiotics are present in a weight ratio Oxytetracycline: Benzylpenicillin: Multimycine in a range varying from 10 to 30, preferably 20, of the first compound, 200 to 300, preferably 150 of the second compound and 1 to 15, preferably 7 of the third compound.
3. Composition according to claim 1 or 2, characterised in that it corresponds to the Galenic formula obtained by mixing the following constituents for 100 ml: 1/ Oxytetracycline HCl 926 V9 2/ Procaine Benzylpenicillin 24000 US 3/ Colistin Sulphate 10 to 100 pg 4/ Polyvidone constituent solvent of the Aqua distil lata ad 1 ml 5/ Magnesium formaldehyde bisulfite 7 mg Magnesium Oxide 7 mg Methyl paraoxybenzoate 0.68 mg Sodium citrate (Vitamin A) 3.5 mg Sodium carboxymethyl cellulose diluent Propyl para hydroxybenzoate 0.12 mg Polyvinyl pyrrolidone diluent 6/ Propyleneglycol 12 mg in so far as solvent
4. Use of a composition according to one of claims 1-3, for combatting infections of the mucous membranes, in particular the mycoses caused by fungi, all the necrotic illnesses, Peritonitis, infectious Pneumonia and the white sickness in Bovines.
5. Antibiotic composition substantially as described herein. Dated this 2nd day of May 1984 (signed)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU84786 | 1983-05-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE841088L IE841088L (en) | 1984-11-03 |
| IE57352B1 true IE57352B1 (en) | 1992-08-12 |
Family
ID=19730090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE1088/84A IE57352B1 (en) | 1983-05-03 | 1984-05-02 | Composition having improved pharmaceutical activity and use of it for veterinary purposes |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0150186A1 (en) |
| JP (1) | JPH01500746A (en) |
| CA (1) | CA1221635A (en) |
| DK (1) | DK3585D0 (en) |
| IE (1) | IE57352B1 (en) |
| IT (1) | IT1180166B (en) |
| PT (1) | PT78540B (en) |
| WO (1) | WO1984004249A2 (en) |
| ZA (1) | ZA843277B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1054681B1 (en) * | 1998-02-02 | 2003-05-07 | Boehringer Ingelheim Vetmedica Gmbh | The use of combinations of active agents consisting of antibiotics and plant extracts containing terpene in veterinary medicine |
| WO2009041832A2 (en) * | 2007-09-25 | 2009-04-02 | Pastoral Greenhouse Gas Research Ltd | Vaccines and vaccine components for inhibition of microbial cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE505709A (en) * | ||||
| FR1602275A (en) * | 1967-12-18 | 1970-11-02 | Tetracycline derivs antibiotics | |
| FR2364653A1 (en) * | 1976-09-20 | 1978-04-14 | Synthelabo | Synergistic antibiotic mixts. - contg. colistin and benzathine benzyl penicillin |
-
1984
- 1984-05-02 ZA ZA843277A patent/ZA843277B/en unknown
- 1984-05-02 WO PCT/BE1984/000012 patent/WO1984004249A2/en not_active Application Discontinuation
- 1984-05-02 CA CA000453413A patent/CA1221635A/en not_active Expired
- 1984-05-02 EP EP84901729A patent/EP0150186A1/en not_active Withdrawn
- 1984-05-02 JP JP59501885A patent/JPH01500746A/en active Pending
- 1984-05-02 IT IT20759/84A patent/IT1180166B/en active
- 1984-05-02 IE IE1088/84A patent/IE57352B1/en not_active IP Right Cessation
- 1984-05-03 PT PT78540A patent/PT78540B/en not_active IP Right Cessation
-
1985
- 1985-01-03 DK DK3585A patent/DK3585D0/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DK3585A (en) | 1985-01-03 |
| PT78540A (en) | 1984-06-01 |
| IT8420759A0 (en) | 1984-05-02 |
| IT1180166B (en) | 1987-09-23 |
| JPH01500746A (en) | 1989-03-16 |
| WO1984004249A3 (en) | 1985-03-14 |
| DK3585D0 (en) | 1985-01-03 |
| IT8420759A1 (en) | 1985-11-02 |
| PT78540B (en) | 1986-07-14 |
| CA1221635A (en) | 1987-05-12 |
| EP0150186A1 (en) | 1985-08-07 |
| ZA843277B (en) | 1984-12-24 |
| IE841088L (en) | 1984-11-03 |
| WO1984004249A2 (en) | 1984-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IE57352B1 (en) | Composition having improved pharmaceutical activity and use of it for veterinary purposes | |
| RU2035186C1 (en) | Prophylactic biopreparation sporolact | |
| US4470978A (en) | Synergistic antibacterial composition | |
| US3949077A (en) | Synergistic antibiotic compositions | |
| DE69004941T2 (en) | Drug formulations to increase the effectiveness of beta-lactam antibiotics in prophylaxis and treatment of infectious disease due to pathogenic bacteria. | |
| JPS59205321A (en) | Anthelmintic synergistical novel composition | |
| DE3153623C2 (en) | ||
| RU2112511C1 (en) | Preparation for prophylaxis and treatment of animals with helminthiasis | |
| RU2212891C2 (en) | Antiparasitic preparation with immunomodulating properties | |
| WO2003070231A1 (en) | Antibacterial compositions | |
| AU648792B2 (en) | Veterinary treatment for pigs | |
| RU2218167C2 (en) | Method for preparing composite agent "ointment "svf" | |
| KR960015952B1 (en) | Antidiarrheial therapeutic agents for animal and the pharmaceutical compositions comprising them | |
| RU2136173C1 (en) | Feed additive | |
| JPS62246517A (en) | Synergistic composition | |
| RU2103997C1 (en) | Medicinal agent for treatment of animal disease of bacterial etiology, method of treatment of animal gastroenteric disease of bacterial etiology and methods of treatment of gynecological disease of bacterial etiology in animals | |
| EP0135657B1 (en) | Antibacterial drugs and/or feed concentrates | |
| NL8501198A (en) | NEW MEDICINAL PRODUCTS WITH ANTIMICROBIAL EFFECT AND METHOD FOR THE PREPARATION THEREOF. | |
| RU2014073C1 (en) | Preparation for prophylaxis of acute gastrointestinal diseases of new-born calves | |
| US5643902A (en) | Veterinary treatment | |
| AU621459B2 (en) | Compositions comprising baquiloprim and sulphadimethoxine | |
| RU1805957C (en) | Method for prevention of acute respiratory disease in calves | |
| RU1793922C (en) | Method of acute respiratory diseases prophylaxis in calves | |
| GB2202144A (en) | Synergistic veterinary compositions and/or fodder premixes | |
| RU1793917C (en) | Method of bronhopneumonia treatment in calves |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed |